Skip to main content

Table 2 Virologic Outcomes of EI-AED Compared to NEI-AED Subjects

From: Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study

 

EI-AED

(N = 19)

NEI-AED

(N = 85)

OR (95% CI) or

Difference ± SE

Adjusted for Year of and VL at

HAART Initiation

OR (95% CI) or

Difference ± SE

First HAART/AED Overlap

    

   Virologic failure

10/16 (62.5%)

20/75 (26.7%)

4.58 (1.47 - 14.25)

P = 0.009

4.67 (0.92 - 23.62)

P = 0.062

   Average VL during period (log10)

3.3 ± 1.3 (n = 19)

2.4 ± 1.2 (n = 84)

0.8 ± 0.3;

P = 0.006

0.2 ± 0.3;

P = 0.376

   VL <400 at 6 months

4/12 (33.3%)

50/70 (71.4%)

0.20 (0.05 - 0.74)

P = 0.016

0.35 (0.06 - 2.07)

P = 0.247

   VL <400 at 12 months

4/11 (36.4%)

42/56 (75.0%)

0.19 (0.05 - 0.75)

P = 0.018

0.17 (0.02 - 1.42)

p = 0.102

All HAART/AED Overlaps*

    

   Virologic failure

19/30 (63.3%)

34/122 (27.9%)

4.29 (1.51 - 12.21)

P = 0.006

4.19 (1.54 - 11.44)

P = 0.005

   Average VL during period (log10)

3.3 ± 1.3 (n = 34)

2.5 ± 1.3 (n = 142)

0.9 ± 0.3

P = 0.005

0.7 ± 0.3

P = 0.007

   VL <400 at 6 months

8/28 (28.6%)

84/121 (69.4%)

0.17 (0.06 - 0.53)

P = 0.002

0.25 (0.07 - 0.86)

P = 0.028

   VL <400 at 12 months

9/23 (39.1%)

71/96 (74.0%)

0.21 (0.07 - 0.61)

P = 0.004

0.22 (0.06 - 0.75)

P = 0.016

  1. OR (odds ratio): Odds of virologic event for EI-AED cases versus odds for NEI-AED controls; VL, viral load (copies/mL); * Up to three intervals used per subject